Fingerpaint Group

Fingerpaint Group is a healthcare marketing and commercialization agency specializing in pharmaceutical, biotech, medical device, and animal health sectors. The company serves as a trusted partner to 95% of the top 20 global pharmaceutical companies and ranks among the top 20 healthcare platforms on the MM&M Agency 100 List.

The agency offers an integrated suite of services spanning marketing, medical communications, medical affairs, market access, branding, multicultural marketing, and media activation. Their approach emphasizes cross-functional collaboration, with two-thirds of their 2024 business leveraging multiple solutions within their portfolio. The company has received five Agency of the Year awards in the past five years and won a CLIO award in a category alongside major consumer brands.

Founded by Ed Mitzen, a four-time healthcare marketing entrepreneur who has built businesses totaling over $1 billion in combined revenue, Fingerpaint Group maintains a senior leadership structure with hands-on client involvement. The agency recently expanded its medical communications capabilities through the acquisition of L&M Healthcare Communications.

Choose Fingerpaint Group when you need a comprehensive commercialization partner with proven experience across the pharmaceutical product lifecycle. The agency excels in situations requiring coordinated execution across multiple disciplines—such as simultaneous brand strategy, medical education, and market access initiatives—backed by senior-level involvement.

Expect an integrated approach where marketing, medical, and commercial teams collaborate across silos. The agency's track record with major pharmaceutical companies suggests capability to handle complex, global product launches and lifecycle management challenges while maintaining creative excellence recognized by industry awards.

Fingerpaint Group exclusively serves the life sciences sector, with deep specialization in pharmaceutical, biotech, medical device, and animal health markets. The agency's healthcare focus is comprehensive, spanning medical communications with scientific rigor, medical affairs support throughout the product lifecycle, and market access strategies for payer engagement. Their acquisition of L&M Healthcare Communications specifically strengthens their ability to deliver scientifically rigorous content for healthcare professional engagement.

The company's entire portfolio is designed around the unique regulatory, scientific, and commercial requirements of bringing healthcare products to market, from early development through commercial launch and lifecycle management.

Ideal clients are established pharmaceutical, biotech, or medical device companies with products in late-stage development or on-market requiring comprehensive commercialization support. Organizations benefit most when they need coordinated services across medical affairs, marketing, and market access, value senior-level strategic involvement, and operate in global markets requiring both U.S. and European capabilities.